Sensitivity analyses of the 5-y PFS with pola-R-CHP in DLBCL (compared with R-CHOP)
| Cost-effectiveness . | Proportion of simulations that pola-R-CHP is cost effective at various WTP thresholds . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 5-y PFS with pola-R-CHP . | Life-years gained . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 US dollars) . | Incremental cost . | ICER . | $50 000 . | $100 000 . | $150 000 . |
| 60% | −0.21 | 9.40 | −1.49 | 446 006 | $103 173 | Dominated | 21% | 26% | 33% |
| 65% | 0.15 | 11.25 | 0.36 | 432 982 | $90 149 | 250 413 | 36% | 44% | 49% |
| 70% | 0.69 | 11.82 | 0.93 | 417 600 | $70 682 | 80 394 | 49% | 57% | 61% |
| 75% | 1.23 | 12.40 | 1.51 | 377 192 | $45 784 | 30 321 | 57% | 67% | 72% |
| Cost-effectiveness . | Proportion of simulations that pola-R-CHP is cost effective at various WTP thresholds . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 5-y PFS with pola-R-CHP . | Life-years gained . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 US dollars) . | Incremental cost . | ICER . | $50 000 . | $100 000 . | $150 000 . |
| 60% | −0.21 | 9.40 | −1.49 | 446 006 | $103 173 | Dominated | 21% | 26% | 33% |
| 65% | 0.15 | 11.25 | 0.36 | 432 982 | $90 149 | 250 413 | 36% | 44% | 49% |
| 70% | 0.69 | 11.82 | 0.93 | 417 600 | $70 682 | 80 394 | 49% | 57% | 61% |
| 75% | 1.23 | 12.40 | 1.51 | 377 192 | $45 784 | 30 321 | 57% | 67% | 72% |
In this table, the 5-year PFS is varied from 60% to 75%, and the clinical outcomes (OS), effectiveness (life-years gained and QALY), and total cost related to DLBCL are displayed.